Nelarabin je organsko jedinjenje, koje sadrži 11 atoma ugljenika i ima molekulsku masu od 297,267 Da.[1][2][3][4][5][6][7]

Nelarabin
Nelarabine structure.svg
Nelarabine ball-and-stick.png
Klinički podaci
Prodajno imeArranon, Arranon (GlaxoSmithKline), Atriance
Drugs.comMonografija
Način primeneIntravenozno
Farmakokinetički podaci
Poluvreme eliminacije30 minuta - 3 h
IzlučivanjeRenalno
Identifikatori
CAS broj121032-29-9 ДаY
ATC kodL01BB07 (WHO)
PubChemCID 3011155
DrugBankDB01280 ДаY
ChemSpider2280207 ДаY
ChEMBLCHEMBL1201112 ДаY
Hemijski podaci
FormulaC11H15N5O5
Molarna masa297,267
  • COC1=NC(N)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
  • InChI=1S/C11H15N5O5/c1-20-9-5-8(14-11(12)15-9)16(3-13-5)10-7(19)6(18)4(2-17)21-10/h3-4,6-7,10,17-19H,2H2,1H3,(H2,12,14,15)/t4-,6-,7+,10-/m1/s1 ДаY
  • Key:IXOXBSCIXZEQEQ-UHTZMRCNSA-N ДаY
Fizički podaci
Tačka topljenja209—217 °C (408—423 °F)

OsobineУреди

Osobina Vrednost
Broj akceptora vodonika 9
Broj donora vodonika 4
Broj rotacionih veza 3
Particioni koeficijent[8] (ALogP) -1,4
Rastvorljivost[9] (logS, log(mol/L)) -0,4
Polarna površina[10] (PSA, Å2) 148,8

ReferenceУреди

  1. ^ Buie LW, Epstein SS, Lindley CM: Nelarabine: a novel purine antimetabolite antineoplastic agent. Clin Ther. 2007 Sep;29(9):1887-99. PMID 18035189
  2. ^ DeAngelo DJ: Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Hematol Oncol Clin North Am. 2009 Oct;23(5):1121-35, vii-viii. PMID 19825456
  3. ^ Roecker AM, Allison JC, Kisor DF: Nelarabine: efficacy in the treatment of clinical malignancies. Future Oncol. 2006 Aug;2(4):441-8. PMID 16922610
  4. ^ Sanford M, Lyseng-Williamson KA: Nelarabine. Drugs. 2008;68(4):439-47. PMID 18318562
  5. ^ Reilly KM, Kisor DF: Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia. Onco Targets Ther. 2009 Feb 18;2:219-28. PMID 20616909
  6. ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.  уреди
  7. ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.  уреди
  8. ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o. 
  9. ^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t.  уреди
  10. ^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e.  уреди

LiteraturaУреди

Spoljašnje vezeУреди

 Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).